Cargando…
Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study
BACKGROUND: Recommendations for secondary hyperparathyroidism (SHPT) consider that a “one-size-fits-all” target enables efficacy of care. In routine clinical practice, SHPT continues to pose diagnosis and treatment challenges. One hypothesis that could explain these difficulties is that dialysis pop...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236624/ https://www.ncbi.nlm.nih.gov/pubmed/25123022 http://dx.doi.org/10.1186/1471-2369-15-132 |
_version_ | 1782345204668301312 |
---|---|
author | Laurain, Emmanuelle Ayav, Carole Erpelding, Marie-Line Kessler, Michèle Briançon, Serge Brunaud, Laurent Frimat, Luc |
author_facet | Laurain, Emmanuelle Ayav, Carole Erpelding, Marie-Line Kessler, Michèle Briançon, Serge Brunaud, Laurent Frimat, Luc |
author_sort | Laurain, Emmanuelle |
collection | PubMed |
description | BACKGROUND: Recommendations for secondary hyperparathyroidism (SHPT) consider that a “one-size-fits-all” target enables efficacy of care. In routine clinical practice, SHPT continues to pose diagnosis and treatment challenges. One hypothesis that could explain these difficulties is that dialysis population with SHPT is not homogeneous. METHODS: EPHEYL is a prospective, multicenter, pharmacoepidemiological study including chronic dialysis patients (≥3 months) with newly SHPT diagnosis, i.e. parathyroid hormone (PTH) ≥500 ng/L for the first time, or initiation of cinacalcet, or parathyroidectomy. Multiple correspondence analysis and ascendant hierarchical clustering on clinico-biological (symptoms, PTH, plasma phosphorus and alkaline phosphatase) and treatment of SHPT (cinacalcet, vitamin D, calcium, or calcium-free calcic phosphate binder) were performed to identify distinct phenotypes. RESULTS: 305 patients (261 with incident PTH ≥ 500 ng/L; 44 with cinacalcet initiation) were included. Their mean age was 67 ± 15 years, and 60% were men, 92% on hemodialysis and 8% on peritoneal dialysis. Four subgroups of SHPT patients were identified: 1/ “intermediate” phenotype with hyperphosphatemia without hypocalcemia (n = 113); 2/ younger patients with severe comorbidities, hyperphosphatemia and hypocalcemia, despite SHPT multiple medical treatments, suggesting poor adherence (n = 73); 3/ elderly patients with few cardiovascular comorbidities, controlled phospho-calcium balance, higher PTH, and few treatments (n = 75); 4/ patients who initiated cinacalcet (n = 43). The quality criterion of the model had a cut-off of 14 (>2), suggesting a relevant classification. CONCLUSION: In real life, dialysis patients with newly diagnosed SHPT constitute a very heterogeneous population. A “one-size-fits-all” target approach is probably not appropriate. Therapeutic management needs to be adjusted to the 4 different phenotypes. |
format | Online Article Text |
id | pubmed-4236624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42366242014-11-19 Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study Laurain, Emmanuelle Ayav, Carole Erpelding, Marie-Line Kessler, Michèle Briançon, Serge Brunaud, Laurent Frimat, Luc BMC Nephrol Research Article BACKGROUND: Recommendations for secondary hyperparathyroidism (SHPT) consider that a “one-size-fits-all” target enables efficacy of care. In routine clinical practice, SHPT continues to pose diagnosis and treatment challenges. One hypothesis that could explain these difficulties is that dialysis population with SHPT is not homogeneous. METHODS: EPHEYL is a prospective, multicenter, pharmacoepidemiological study including chronic dialysis patients (≥3 months) with newly SHPT diagnosis, i.e. parathyroid hormone (PTH) ≥500 ng/L for the first time, or initiation of cinacalcet, or parathyroidectomy. Multiple correspondence analysis and ascendant hierarchical clustering on clinico-biological (symptoms, PTH, plasma phosphorus and alkaline phosphatase) and treatment of SHPT (cinacalcet, vitamin D, calcium, or calcium-free calcic phosphate binder) were performed to identify distinct phenotypes. RESULTS: 305 patients (261 with incident PTH ≥ 500 ng/L; 44 with cinacalcet initiation) were included. Their mean age was 67 ± 15 years, and 60% were men, 92% on hemodialysis and 8% on peritoneal dialysis. Four subgroups of SHPT patients were identified: 1/ “intermediate” phenotype with hyperphosphatemia without hypocalcemia (n = 113); 2/ younger patients with severe comorbidities, hyperphosphatemia and hypocalcemia, despite SHPT multiple medical treatments, suggesting poor adherence (n = 73); 3/ elderly patients with few cardiovascular comorbidities, controlled phospho-calcium balance, higher PTH, and few treatments (n = 75); 4/ patients who initiated cinacalcet (n = 43). The quality criterion of the model had a cut-off of 14 (>2), suggesting a relevant classification. CONCLUSION: In real life, dialysis patients with newly diagnosed SHPT constitute a very heterogeneous population. A “one-size-fits-all” target approach is probably not appropriate. Therapeutic management needs to be adjusted to the 4 different phenotypes. BioMed Central 2014-08-13 /pmc/articles/PMC4236624/ /pubmed/25123022 http://dx.doi.org/10.1186/1471-2369-15-132 Text en Copyright © 2014 Laurain et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Laurain, Emmanuelle Ayav, Carole Erpelding, Marie-Line Kessler, Michèle Briançon, Serge Brunaud, Laurent Frimat, Luc Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study |
title | Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study |
title_full | Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study |
title_fullStr | Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study |
title_full_unstemmed | Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study |
title_short | Targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? A prospective incident cohort study |
title_sort | targets for parathyroid hormone in secondary hyperparathyroidism: is a “one-size-fits-all” approach appropriate? a prospective incident cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236624/ https://www.ncbi.nlm.nih.gov/pubmed/25123022 http://dx.doi.org/10.1186/1471-2369-15-132 |
work_keys_str_mv | AT laurainemmanuelle targetsforparathyroidhormoneinsecondaryhyperparathyroidismisaonesizefitsallapproachappropriateaprospectiveincidentcohortstudy AT ayavcarole targetsforparathyroidhormoneinsecondaryhyperparathyroidismisaonesizefitsallapproachappropriateaprospectiveincidentcohortstudy AT erpeldingmarieline targetsforparathyroidhormoneinsecondaryhyperparathyroidismisaonesizefitsallapproachappropriateaprospectiveincidentcohortstudy AT kesslermichele targetsforparathyroidhormoneinsecondaryhyperparathyroidismisaonesizefitsallapproachappropriateaprospectiveincidentcohortstudy AT brianconserge targetsforparathyroidhormoneinsecondaryhyperparathyroidismisaonesizefitsallapproachappropriateaprospectiveincidentcohortstudy AT brunaudlaurent targetsforparathyroidhormoneinsecondaryhyperparathyroidismisaonesizefitsallapproachappropriateaprospectiveincidentcohortstudy AT frimatluc targetsforparathyroidhormoneinsecondaryhyperparathyroidismisaonesizefitsallapproachappropriateaprospectiveincidentcohortstudy |